Predict your next investment

Corporation
HEALTHCARE | Disease Diagnosis
vyantbio.com

See what CB Insights has to offer

Stage

IPO | IPO

Total Raised

$6.88M

Date of IPO

4/5/2013

Market Cap

0.06B

About VyantBio

VyantBio is a provider in the field of personalized medicine, offering products and services that enable cancer diagnostics as well as treatments that are tailored to the specific genetic profile of the individual. The company develops products and services to transform cancer patient management, increase treatment efficacy, and reduce healthcare costs. CGI's tests and reference laboratory provide critical genomic information where patients and their physicians need it most - to diagnose, monitor and inform cancer treatment.

VyantBio Headquarter Location

201 Route 17 North 2nd Floor

Rutherford, New Jersey, 07070,

United States

201-528-9200

Latest VyantBio News

Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference

Nov 10, 2021

During the presentation, Vyant Bio’s Chief Executive Officer, Jay Roberts, will highlight the Company's addition of its Chief Scientific Officer, progress being made with its drug discovery programs, noteworthy collaborations and partnerships, and the broader going-forward corporate strategy. The presentation will be webcast and an archived recording will be made available in the Investors’ section of the Vyant Bio website and also on the Q4 Investor Summit website for 90 days following the event. If you are an investor and would like to attend the Q4 Investor Summit, please click on the following link ( https://investorsummitgroup.com ) to register. Once your registration is confirmed, you will be prompted to log into the conference website and will be able to request a one-on-one meeting with the Company. Vyant Bio will also be available for virtual outside 1:1 meetings both during and after the Q4 Investor Summit Micro & Small Cap Conference. Please contact Jennifer K. Zimmons, PhD at jzimmons@zimmonsic.com or +1 917.214.3514 for scheduling. ABOUT VYANT BIO, INC. Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT) has developed a drug discovery engine centered on revolutionary human-derived biology that incorporates advanced technology driven chemistry, data science, and engineering with global regulatory expertise. Through multiple in silico, in vitro, and in vivo modalities, Vyant Bio rapidly identifies and designs small and large molecule therapeutics that are derisked in human biology much earlier, and have lower costs and failure rates compared to traditional discovery platforms. The Company is focused on efficiently discovering neurology and oncology drugs and, going forward, plans to file two investigational new drug applications annually. Vyant Bio is headquartered in the US, with offices in Europe, and research facilities in Australia. The Company has five state-of-the-art labs and a scientific team with world experts in key areas who have been involved in over 200 investigational new drug applications and over 50 CNS and oncology studies and trials. For more information, please visit or follow Vyant Bio at: Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability and increase sales of our services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger of StemoniX, Inc. and Cancer Genetics, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements. Investor Contact: Investor Relations

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing VyantBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

VyantBio is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

VyantBio Patents

VyantBio has filed 11 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/23/2014

10/13/2015

Infectious causes of cancer, Papillomavirus, Transcription factors, Vaccines, Molecular biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/23/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/13/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Infectious causes of cancer, Papillomavirus, Transcription factors, Vaccines, Molecular biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

VyantBio Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

VyantBio Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.